Decreased total lymphocyte counts in pancreatic cancer: An index of adverse outcome

被引:210
作者
Fogar, P
Sperti, C
Basso, D
Sanzari, MC
Greco, E
Davoli, C
Navaglia, F
Zambon, CF
Pasquali, C
Venza, E
Pedrazzoli, S
Plebani, M
机构
[1] Univ Padua, Dept Lab Med, I-35128 Padua, Italy
[2] Univ Padua, Dept Med & Surg Sci, I-35128 Padua, Italy
[3] S Giacomo Hosp, Operat Unit Histopathol Anat, Castelfranco Veneto, Italy
关键词
chronic pancreatitis; clusters of differentiation; lymphocytes; pancreatic cancer; survival;
D O I
10.1097/01.mpa.0000188305.90290.50
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objectives: An impaired host immunity might concur in determining the dismal prognosis of patients with pancreatic cancer (PC). Our aim was to ascertain whether the immunophenotype pattern of blood lymphocytes in PC correlates with tumor stage, grade, or survival. Methods: We studied 115 patients with PC, 44 with chronic pancreatitis (CP), 23 with tumors of the pancreatico-biliary tract, and 34 healthy controls (CS). Survival data were available for 77 patients with PC. Lymphocyte subsets were determined by fluorescent activated cell sorter (FACS) analysis. Results: In patients with PC, total lymphocyte counts were lower than in CP or CS, and CD8(+) lymphocyte subset levels were higher with respect to CS. Lower circulating lymphocytes were found in advanced PC stages ( IIB - IV; chi(2) = 11.55, P < 0.05) compared with stages 0 to IIA. Cox regression analysis, made considering total lymphocyte counts and tumor stage as covariates, was found to be significant for both tumor stage ( P< 0.001) and total lymphocyte counts ( P< 0.05). Conclusions: The reduction of total lymphocytes in blood is the main immunologic change in advanced PC. The survival of these patients depends mainly on tumor stage, but it is also affected by the number of circulating lymphocytes, suggesting that the immune system plays an important role in pancreatic adenocarcinoma immunosurveillance and immunoediting.
引用
收藏
页码:22 / 28
页数:7
相关论文
共 46 条
  • [1] Immune responses in cancer
    Adam, JK
    Odhav, B
    Bhoola, KD
    [J]. PHARMACOLOGY & THERAPEUTICS, 2003, 99 (01) : 113 - 132
  • [2] Ademmer K, 1998, CLIN EXP IMMUNOL, V112, P21
  • [3] Escape from immunotherapy: possible mechanisms that influence tumor regression/progression
    Ahmad, M
    Rees, RC
    Ali, SA
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (10) : 844 - 854
  • [4] Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas
    Ammori, JB
    Colletti, LM
    Zalupski, MM
    Eckhauser, FE
    Greenson, JK
    Dimick, Y
    Lawrence, TS
    McGinn, CY
    [J]. JOURNAL OF GASTROINTESTINAL SURGERY, 2003, 7 (06) : 766 - 772
  • [5] Pancreatic cancer biology and genetics
    Bardeesy, N
    DePinho, RA
    [J]. NATURE REVIEWS CANCER, 2002, 2 (12) : 897 - 909
  • [6] The genetics of pancreatic cancer
    Cowgill, SM
    Muscarella, P
    [J]. AMERICAN JOURNAL OF SURGERY, 2003, 186 (03) : 279 - 286
  • [7] The immunobiology of cancer immunosurveillance and immunoediting
    Dunn, GP
    Old, LJ
    Schreiber, RD
    [J]. IMMUNITY, 2004, 21 (02) : 137 - 148
  • [8] Metastatic pancreatic cancer: Emerging strategies in chemotherapy and palliative care
    El Kamar, FG
    Grossbard, ML
    Kozuch, PS
    [J]. ONCOLOGIST, 2003, 8 (01) : 18 - 34
  • [9] Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma
    Esposito, I
    Menicagli, M
    Funel, N
    Bergmann, F
    Boggi, U
    Mosca, F
    Bevilacqua, G
    Campani, D
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2004, 57 (06) : 630 - 636
  • [10] Killer genes in pancreatic cancer therapy
    Fogar, P
    Greco, E
    Basso, D
    Navaglia, F
    Plebani, M
    Pedrazzoli, S
    [J]. CELLULAR AND MOLECULAR BIOLOGY, 2005, 51 (01) : 61 - 76